New drug cocktail shows early promise for tough lung cancer

NCT ID NCT04612751

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without chemotherapy, in 155 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and shows signs of shrinking tumors. It is not yet known if this approach will work better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Datopotamab deruxtecan (Dato-DXd) combined with immunotherapy drugs (durvalumab, rilvegostomig, or volrustomig) and sometimes carboplatin
What this could lead to: If this works, it could point toward a new combination treatment for advanced lung cancer that may shrink tumors and delay progression.
What could go wrong: This is a very early (Phase 1b) study focused on safety, not yet proven to work. Side effects from combining these drugs could be significant, and the benefit may be limited or not confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC NSCLC

Contacts and locations

Locations

Research Site

Taipei, 100, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taoyuan, 00333, Taiwan
Research Site

Adana, 01060, Turkey (Türkiye)
Research Site

Ankara, 06800, Turkey (Türkiye)
Research Site

Ankara, 6200, Turkey (Türkiye)
Research Site

Istanbul, 34010, Turkey (Türkiye)
Research Site

Izmir, 35330, Turkey (Türkiye)
Research Site

Hsinchu, 300, Taiwan
Research Site

La Jolla, California, 92093, United States
Research Site

Santa Ana, California, 92705, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Hackensack, New Jersey, 07601, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Dallas, Texas, 75230, United States
Research Site

Houston, Texas, 77030, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Hasselt, 3500, Belgium
Research Site

Roeselare, 8800, Belgium
Research Site

Aviano, 33081, Italy
Research Site

Meldola, 47014, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Roma, 00144, Italy
Research Site

Kōtoku, 135-8550, Japan
Research Site

Sunto-gun, 411-8777, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

Gdansk, 80-952, Poland
Research Site

Lodz, 93-338, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

A Coruña, 15005, Spain
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 8036, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28046, Spain
Research Site

Madrid, 28050, Spain
Research Site

Seville, 41015, Spain
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.